One of China's First GMP-Certified Biopharmaceutical Enterprises

Beijing Tri-Prime Gene Pharmaceutical Co, Ltd. (Abbr.: Tri-Prime Gene, stock code: 837344) with a registered capital of RMB 121.81 million, specializes in R&D, production, and commercialization of modern biopharmaceuticals, establishing itself as a leader in both fundamental research and clinical application of gene engineering drugs in China.

Learn More
  •  
    +

    effective invention patents

  •  

    1992~2025

Deep Cultivation in the Field of Interferon for 30 Years

Product Center

Hapgen ® Spray

Recombinant Human Interferon α1b Spray

National "863" program and national "11th Five-Year Plan" major new drug innovation technology major project "Biological large varieties transformation projects", treating common skin viral infections - facial simplex herpes, promoting skin healing, reduc

Learn More

Hapgen ® Eye Drops

Human Interferon α1b Eye Drops

National "11th Five-Year Plan" Major New Drug Development and Manufacturing Technology Project "Biological Large Variety Reform Project", for the treatment of common acquired blindness diseases - simplex herpes virus keratitis.

Learn More

Hapgen ® Powder Injection

Injected Human Interferon α1b

Class I new drug, national key new product, Beijing's major technological achievement promotion plan project. Treatment of viral infections and some malignant tumors.

Learn More

Hapgen® Injection

Human Interferon α1b Injection

National key new product, Beijing's independent innovation product, Beijing's major high-tech achievement transformation project, Zhongguancun National Independent Innovation Demonstration Zone new technology, new product (service), treating viral infecti

Learn More

Lishuxing® Antiviral Oral Spray

Antiviral Oral Spray

A novel broad-spectrum antimicrobial therapeutic product. Provides both symptomatic and causal treatment, with dual preventive-therapeutic effects, wide applicability, and convenient usage.

Learn More

Pioneering Enterprise in China's Biopharmaceutical Industry

Core technology

微信公众号

不良反应报告